Larimar Therapeutics, Inc.(LRMR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LRMR Larimar Therapeutics, Inc.

休市中 08-16 16:00:00 EDT

7.59

-0.20

-2.57%

盘后7.59

+0.000.00%

16:12 EDT

最高7.89	最低7.49	成交量50.43万
今开7.80	昨收7.79	日振幅5.13%
总市值4.84亿	流通市值2.41亿	总股本6,381万
成交额384.02万	换手率1.59%	流通股本3,179万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":7.59,"timestamp":1723838400000,"preClose":7.79,"halted":0,"volume":504336,"hourTrading":{"tag":"盘后","latestPrice":7.59,"preClose":7.59,"latestTime":"16:12 EDT","volume":213297,"amount":1618924.23,"timestamp":1723839163318},"delay":0,"floatShares":31790631,"shares":63806628,"eps":-1.137385,"marketStatus":"休市中","marketStatusCode":7,"change":-0.2,"latestTime":"08-16 16:00:00 EDT","open":7.8,"high":7.89,"low":7.49,"amount":3840162.830952,"amplitude":0.051348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.137385,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724054400000},"adr":0,"listingDate":1403150400000,"adjPreClose":7.79,"preHourTrading":{"tag":"盘前","latestPrice":7.79,"preClose":7.79,"latestTime":"08:05 EDT","volume":1,"amount":7.79,"timestamp":1723809941137},"postHourTrading":{"tag":"盘后","latestPrice":7.59,"preClose":7.59,"latestTime":"16:12 EDT","volume":213297,"amount":1618924.23,"timestamp":1723839163318},"volumeRatio":1.914076,"impliedVol":0.8763,"impliedVolPercentile":0.1786},"requestUrl":"/m/hq/s/LRMR/tweets","defaultTab":"tweets","newsList":[{"id":"2460241545","title":"Larimar Therapeutics, Inc.2024财年第二财季实现净利润-21.63百万美元，同比减少158.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460241545","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460241545?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:00","pubTimestamp":1723824038,"startTime":"0","endTime":"0","summary":"8月17日，Larimar Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-21.63百万美元，同比减少158.42%；其中营业收入为0.00美元，每股基本收益为-0.34美元。从资产负债表来看，Larimar Therapeutics, Inc.总负债25.76百万美元，其中短期债务992000.00美元，资产负债比为0.10，流动比率为0.11。机构评级：截至2024年8月17日，当前有6家机构对Larimar Therapeutics, Inc.目标价做出预测，其中目标均价为22.35美元，其中最低目标价为9.12美元，最高目标价为36.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000615959f2d63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000615959f2d63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LRMR","LENZ"],"gpt_icon":0},{"id":"2457778570","title":"Larimar Therapeutics Inc   预计每股亏损31美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457778570","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457778570?lang=zh_cn&edition=full","pubTime":"2024-08-07 02:32","pubTimestamp":1722969166,"startTime":"0","endTime":"0","summary":"   * Larimar Therapeutics Inc    预计在8月8日公布截至2024年6月30日的财报时，季度营收将不会有任何变化(预计)    *    * LSEG 的分析师平均预计 Larimar Therapeutics Inc 每股亏损 31 美分。* 华尔街对 Larimar Therapeutics Inc 的 12 个月目标价中位数为 25.00 美元，高于其最新收盘价 7.42 美元。8月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LRMR"],"gpt_icon":0},{"id":"2457778159","title":"Larimar Therapeutics, Inc.盘中异动 快速下跌6.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457778159","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457778159?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:38","pubTimestamp":1722865104,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时38分，Larimar Therapeutics, Inc.股票出现异动，股价快速下挫6.25%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.94%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213824957f3238&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213824957f3238&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LRMR","BK4139","LENZ"],"gpt_icon":0},{"id":"2452361324","title":"Larimar Therapeutics, Inc.盘中异动 临近午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452361324","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452361324?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:44","pubTimestamp":1721317441,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日23时44分，Larimar Therapeutics, Inc.股票出现异动，股价大幅下挫5.05%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.88%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。消息层面，截至23时44分，《LifeSci Capital维持Larimar Therapeutics买入评级，维持目标价36美元》资讯为影响Larimar Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718234402af930065&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718234402af930065&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","LRMR"],"gpt_icon":0},{"id":"2452152432","title":"Larimar Therapeutics, Inc.盘中异动 早盘股价大跌5.01%报10.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452152432","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452152432?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:31","pubTimestamp":1721223100,"startTime":"0","endTime":"0","summary":"北京时间2024年07月17日21时31分，Larimar Therapeutics, Inc.股票出现异动，股价急速下跌5.01%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。消息层面，截至21时31分，《LifeSci Capital维持Larimar Therapeutics买入评级，维持目标价36美元》资讯为影响Larimar Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407172131419681da64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407172131419681da64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LRMR","BK4139"],"gpt_icon":0},{"id":"2450028296","title":"Larimar Therapeutics, Inc.盘中异动 股价大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450028296","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450028296?lang=zh_cn&edition=full","pubTime":"2024-07-09 21:31","pubTimestamp":1720531888,"startTime":"0","endTime":"0","summary":"北京时间2024年07月09日21时31分，Larimar Therapeutics, Inc.股票出现异动，股价快速拉升5.13%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Soligenix, Inc.、Uniqure N.V.、Nls Pharmaceutics Ltd C/Wts 02/02/2026涨幅较大，Soligenix, Inc.、Anew Medical, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为2735.40%、90.16%、80.25%，振幅较大的相关个股有Soligenix, Inc.、Uniqure N.V.、Anew Medical, Inc.，振幅分别为25.99%、17.03%、11.72%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709213128aef8b9ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709213128aef8b9ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LRMR","BK4139"],"gpt_icon":0},{"id":"2442520725","title":"Larimar Therapeutics, Inc.盘中异动 早盘大幅上涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442520725","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442520725?lang=zh_cn&edition=full","pubTime":"2024-06-12 21:32","pubTimestamp":1718199141,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日21时32分，Larimar Therapeutics, Inc.股票出现异动，股价大幅拉升5.46%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213222941ee0c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213222941ee0c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LRMR","LENZ"],"gpt_icon":0},{"id":"2440233730","title":"Larimar Therapeutics, Inc.盘中异动 早盘大幅拉升6.56%报9.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440233730","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440233730?lang=zh_cn&edition=full","pubTime":"2024-06-04 21:32","pubTimestamp":1717507930,"startTime":"0","endTime":"0","summary":"北京时间2024年06月04日21时32分，Larimar Therapeutics, Inc.股票出现异动，股价快速拉升6.56%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604213211aef35535&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604213211aef35535&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","LRMR"],"gpt_icon":0},{"id":"2439911457","title":"摩根大通证券公司：重申Larimar Therapeutics(LRMR.US)评级，由优于大市调整至优于大市评级, 目标价由25.","url":"https://stock-news.laohu8.com/highlight/detail?id=2439911457","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439911457?lang=zh_cn&edition=full","pubTime":"2024-05-31 23:46","pubTimestamp":1717170365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4139","159848","LRMR","399975"],"gpt_icon":0},{"id":"2438306607","title":"Larimar Therapeutics, Inc.盘中异动 早盘股价大涨5.65%报7.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438306607","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438306607?lang=zh_cn&edition=full","pubTime":"2024-05-28 22:57","pubTimestamp":1716908261,"startTime":"0","endTime":"0","summary":"北京时间2024年05月28日22时57分，Larimar Therapeutics, Inc.股票出现波动，股价快速上涨5.65%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.81%。其相关个股中，Insmed Incorporated、Calliditas Therapeutics Ab、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Exicure, Inc.、Mustang Bio, Inc.、Scorpius Holdings, Inc.较为活跃，换手率分别为55.94%、44.83%、17.35%，振幅较大的相关个股有Exicure, Inc.、Mustang Bio, Inc.、G1 Therapeutics, Inc.，振幅分别为76.39%、28.59%、27.87%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528225741941eaa68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528225741941eaa68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LRMR","LENZ"],"gpt_icon":0},{"id":"2438630900","title":"Larimar Therapeutics, Inc.盘中异动 急速下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2438630900","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438630900?lang=zh_cn&edition=full","pubTime":"2024-05-25 01:17","pubTimestamp":1716571079,"startTime":"0","endTime":"0","summary":"北京时间2024年05月25日01时17分，Larimar Therapeutics, Inc.股票出现异动，股价快速跳水5.07%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.00%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。该信息摘要如下：花旗：维持Larimar Therapeutics评级，由买入调整至买入评级, 目标价由10.00美元调整至14.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240525011759af8a3111&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240525011759af8a3111&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","LRMR"],"gpt_icon":0},{"id":"2437929633","title":"Larimar Therapeutics, Inc.盘中异动 股价大涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437929633","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437929633?lang=zh_cn&edition=full","pubTime":"2024-05-22 21:34","pubTimestamp":1716384864,"startTime":"0","endTime":"0","summary":"北京时间2024年05月22日21时34分，Larimar Therapeutics, Inc.股票出现异动，股价急速拉升5.45%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.49%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。该信息摘要如下：摩根大通证券公司：重申Larimar Therapeutics评级，由优于大市调整至优于大市评级, 目标价25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405222134259680f126&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405222134259680f126&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LRMR","LENZ"],"gpt_icon":0},{"id":"2437475255","title":"隔夜美股全复盘(5.22)| 特斯拉大涨7%，将其在美国的72个月贷款利率从0.99％提高到1.99％，释放电动汽车需求的积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2437475255","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437475255?lang=zh_cn&edition=full","pubTime":"2024-05-22 05:11","pubTimestamp":1716325908,"startTime":"0","endTime":"0","summary":"特斯拉大涨7%，将其在美国的72个月贷款利率从0.99％提高到1.99％，释放电动汽车需求的积极信号","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/746394","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["PSX","IE00BFTCPJ56.SGD","BK4503","IE00BMPRXN33.USD","EVS.SI","IE00BKDWB100.SGD","LLY","BK4524","MSFT","LU0300736492.USD","BZ","BK4220","BK4528","LU0308772762.SGD","LU2326559502.SGD","LU0109391861.USD","LU0417517546.SGD","LU0211328371.USD","GB00B4LPDJ14.GBP","LU1551013342.USD","IE00BJJMRX11.SGD","BK4561","LRMR","ZM","TSLL","BK4555","LU0238689110.USD","LU0820561909.HKD","BK4592","AMZN","BK4526","IE00BLSP4452.SGD","NVDA","IE00BDCRKT87.USD","BK4543","LU1548497426.USD","IE00B1BXHZ80.USD","LU1852331112.SGD","LU0198837287.USD","IE00BFSS8Q28.SGD","BK4587","TSLA","XPEV","LU0053666078.USD","BK4516","IE00BJJMRY28.SGD","LU0310799852.SGD","BK4551","IBM","LU0820561818.USD"],"gpt_icon":1},{"id":"2437742357","title":"摩根大通证券公司：重申Larimar Therapeutics(LRMR.US)评级，由优于大市调整至优于大市评级, 目标价25.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2437742357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437742357?lang=zh_cn&edition=full","pubTime":"2024-05-22 00:44","pubTimestamp":1716309895,"startTime":"0","endTime":"0","summary":"摩根大通证券公司：重申Larimar Therapeutics(LRMR.US)评级，由优于大市调整至优于大市评级, 目标价25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405220044588b20c467&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405220044588b20c467&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LRMR","LENZ"],"gpt_icon":0},{"id":"2437549955","title":"美股异动 | Larimar Therapeutics盘前涨16% FDA取消旗下部分临床限制罕见疾病疗法新药研发商Larimar Therapeutics(LRMR.","url":"https://stock-news.laohu8.com/highlight/detail?id=2437549955","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437549955?lang=zh_cn&edition=full","pubTime":"2024-05-21 17:04","pubTimestamp":1716282262,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LENZ","LRMR","BK4139"],"gpt_icon":0},{"id":"2437960094","title":"BUZZ-Larimar 因 FDA 撤销遗传病疗法的部分临床搁置而飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2437960094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437960094?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:59","pubTimestamp":1716281950,"startTime":"0","endTime":"0","summary":"    5月21日 - ** 药物开发商Larimar Therapeutics   股价盘前上涨18%至8.58美元** 该公司称  美国食品和药物管理局已经取消了之前对其实验性遗传病疗法Nomlabofusp的部分临床搁置。** Nomlabofusp正在作为弗里德雷氏共济失调症的潜在治疗方法进行测试，该病是一种罕见的遗传性疾病，会导致神经系统损伤和运动障碍。** FDA在对Co公司最近完成的为期四周的中期试验数据进行审查后，取消了部分临床搁置。** LRMR计划在下半年提交该疗法的上市申请** 截至上次收盘，股价累计上涨59.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BK4139","LRMR"],"gpt_icon":0},{"id":"2437648854","title":"【Larimar Therapeutics(LRMR.US)盘后涨近23%！FDA取消旗下FA疗法Nomlabofusp部分临床限制】智通财经APP获悉，有消息称，美国食品药品监督管理局(FDA)在对罕见疾病疗法新药研发商Larimar Therapeutics(LRMR.","url":"https://stock-news.laohu8.com/highlight/detail?id=2437648854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437648854?lang=zh_cn&edition=full","pubTime":"2024-05-21 14:43","pubTimestamp":1716273809,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4535","BK4130","LRMR","BK4539","LENZ","BK4139","FA"],"gpt_icon":0},{"id":"2437610064","title":"Larimar Therapeutics(LRMR.US)盘后涨近23%！FDA取消旗下FA疗法Nomlabofusp部分临床限制","url":"https://stock-news.laohu8.com/highlight/detail?id=2437610064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437610064?lang=zh_cn&edition=full","pubTime":"2024-05-21 14:43","pubTimestamp":1716273809,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，有消息称，美国食品药品监督管理局在对罕见疾病疗法新药研发商Larimar Therapeutics旗下Nomlabofusp临床项目进行了二期数据审查后，取消了对该药物的部分临床限制。受此消息提振，Larimar Therapeutics周一美股盘后涨近23%。据悉，Larimar Therapeutics是一家专注于开发复杂罕见疾病治疗方法的临床阶段生物技术公司。该公司的目标是在2025年下半年提交FDA市场申请。其他开发Friedreich共济失调疗法的公司包括PTC Therapeutics和Design Therapeutics。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4139","BK4130","BK4539","BK4535","FA","LRMR"],"gpt_icon":0},{"id":"2437482159","title":"BUZZ-Larimar Therapeutics 因美国 FDA 撤销遗传病疗法的部分临床搁置而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2437482159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437482159?lang=zh_cn&edition=full","pubTime":"2024-05-21 04:39","pubTimestamp":1716237568,"startTime":"0","endTime":"0","summary":"    5月20日 - ** 药物开发商 Larimar Therapeutics   股价在午后交易中上涨 22.6% 至 8.91 美元 ** 公司称美国 FDA 已经取消了之前对其实验性遗传病疗法的部分临床搁置 ** LRMR正在测试一种名为nomlabofusp的疗法，它可能用于治疗弗里德雷希共济失调症，这是一种罕见的遗传性疾病，会导致进行性神经系统损伤和运动障碍。** 美国食品药品管理局在审查了该公司最近完成的为期四周的中期试验数据后，取消了部分临床搁置。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BUZZ","BK4139","LRMR"],"gpt_icon":0},{"id":"2434517338","title":"Larimar Therapeutics, Inc.盘中异动 急速跳水5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434517338","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434517338?lang=zh_cn&edition=full","pubTime":"2024-05-10 21:39","pubTimestamp":1715348388,"startTime":"0","endTime":"0","summary":"北京时间2024年05月10日21时39分，Larimar Therapeutics, Inc.股票出现波动，股价快速跳水5.45%。Larimar Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Larimar Therapeutics, Inc.公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240510213949861ec6e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240510213949861ec6e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LRMR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zafgen.com","stockEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.2478},{"period":"3month","weight":0.0285},{"period":"6month","weight":-0.4061},{"period":"1year","weight":0.9215},{"period":"ytd","weight":0.6681}],"compareEarnings":[{"period":"1week","weight":0.04},{"period":"1month","weight":-0.0047},{"period":"3month","weight":0.047},{"period":"6month","weight":0.1097},{"period":"1year","weight":0.2705},{"period":"ytd","weight":0.1662}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Larimar Therapeutics, Inc.是根据美国特拉华州法律于2005年11月22日注册成立。公司是一家生物制药公司，致力于显著改善因肥胖而影响身体健康的患者。 Beloranib是公司领先的候选产品，是一种新型的一级产品，用于多种适应症，包括肥胖和饮食过量的普拉德 - 威利综合症患者，与颅咽管瘤相关的肥胖，一般人群严重的母体肥胖等方面的治疗，该产品的用法是每周两次皮下注射。公司自成立以来，一直致力于研究和开发产品、招聘管理、收购经营性资产和筹集资金。因此，公司被认为是处于发展阶段。","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.113505},{"month":2,"riseRate":0.6,"avgChangeRate":0.079231},{"month":3,"riseRate":0.3,"avgChangeRate":-0.13057},{"month":4,"riseRate":0.3,"avgChangeRate":-0.054337},{"month":5,"riseRate":0.5,"avgChangeRate":-0.086037},{"month":6,"riseRate":0.5,"avgChangeRate":-0.021475},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.041896},{"month":8,"riseRate":0.454545,"avgChangeRate":0.0811},{"month":9,"riseRate":0.5,"avgChangeRate":0.029093},{"month":10,"riseRate":0.6,"avgChangeRate":-0.081318},{"month":11,"riseRate":0.7,"avgChangeRate":0.078152},{"month":12,"riseRate":0.6,"avgChangeRate":0.092014}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Larimar Therapeutics, Inc.(LRMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Larimar Therapeutics, Inc.(LRMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}